The Medical Letter on Drugs and Therapeutics
Rapid-Acting Insulin Analogues
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Three rapid-acting insulin analogs are currently available: insulin lispro, insulin aspart and insulin glulisine.1-3 All three are approved for use in both type 1 and type 2 diabetes, either by subcutaneous injection, insulin pump or intravenous administration. All three cost more than regular insulin.

PHARMACOLOGY — Rapid-acting insulin analogs produced via recombinant DNA technology have less tendency than regular insulin to form hexamer aggregates that slow absorption. Therefore, they have a more rapid onset and shorter duration of action.

CLINICAL STUDIES — All three insulin analogs are more effective than regular insulin in decreasing postprandial hyperglycemia.4 All three decrease hemoglobin A1C only slightly more than regular insulin does.5 Compared to regular insulin, lispro has been ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Rapid-Acting Insulin Analogues
Article code: 1327b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian